Published in Gene Therapy Weekly, October 7th, 2004
This trial, with active sites in the United Kingdom and Canada, will represent the first human experience with IR103, which combines the Company's patented HIV-1 Immunogen with Amplivax, an immunostimulatory oligonucleotide adjuvant.
The 2-part, 9-arm, randomized, single-blind, controlled, multi-center phase 1/2 study began this summer and will run for approximately 28 weeks with 80...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.